Teva's 1st-qtr sales down, mainly hit by Copaxone competition
Supreme Court to Hear Appeal of Generic Drug Case - The New York Times
Teva Europe (@tevapharmeurope) / Twitter
Multiple Sclerosis Drugs Market to reach US$ 32 bn by 2027
Multiple Sclerosis Treatment Market Projected to Grow
Teva's MS Drug Copaxone Looking for Approval in Japan - Jewish Business News
Feds accuse Teva of $300M in kickbacks for MS drug - Drug Discovery and Development
Swedish Biotech Faces Another Phase III Flop in Multiple Sclerosis
In blow to Teva, UK court rules in favor of Copaxone patent challenge | The Times of Israel
Teva Pharmaceutical (1): MS and Copaxone – shiqiv.com
Shlomo Yanai, Teva's president and chief executive, addresses the media during a news conference in Tel Aviv July 27, 2010. Teva Pharmaceutical Industries, the world's largest generic drugmaker, reported higher quarterly net
Payers keep squeezing MS drugmakers--and they may just take their tactics elsewhere | Fierce Pharma
EU launches antitrust probe against Teva - www.israelhayom.com
Russia approves three-times-a-week Copaxone 40 mg/ml for treatment of RRMS - Pharmaceutical Business review
Teva embroiled in Copaxone dosage levels dispute - Globes
2023 Multiple Sclerosis Treatment Market Analysis by Solution
Multiple sclerosis and drug discovery: A work of translation - eBioMedicine
Teva, Takeda To Commercialize Multiple Sclerosis Drug - Asian Scientist Magazine
Exclusive: Makers took big price increases on widely used U.S. drugs
High-dose Copaxone the right medicine for Teva | Pharmafile
Teva faces EU antitrust probe over MS drug Copaxone -
One, two, three, gone: Teva loses third patent on new Copaxone formula | Fierce Pharma
First-line disease modifying drugs in multiple sclerosis | Download Table
